Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis
NCT00604682
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
19
Enrollment
INDUSTRY
Sponsor class
Conditions
Psoriasis
Interventions
DRUG:
CC10004
Sponsor
Amgen